Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BB-1701 in HER2-mutated advanced or metastatic non-small cell lung cancer
CTR20231518Phase 2Active
- Sponsor
- Bliss Biopharmaceutical
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BB-1701 in non-small cell lung cancer (NSCLC), sponsored by Bliss Biopharmaceutical. Started Oct 2023; status: active.
02
Drugs
BB-1701
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231518.